MiR-15a, miR-16-1 and miR-17-92 cluster expression are linked to poor prognosis in multiple myeloma

• Published in: Leukemia research Vol. 36; no. 12; pp. 1505 - 1509
• Main Authors: Gao, Xiao, Zhang, Run, Qu, Xiaoyan, Zhao, Min, Zhang, Sensen, Wu, Hanxin, Jianyong, Li, Chen, Lijuan
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.12.2012
• Subjects: Adult; Aged; Aged, 80 and over; Antineoplastic Agents - pharmacology; Antineoplastic Agents - therapeutic use; Apoptosis; Cell proliferation; chromosome 13; Chromosome Deletion; Chromosomes, Human, Pair 13; Data processing; del; Differentiation; Disease-Free Survival; Female; Gene Expression Regulation, Neoplastic; Genomic Instability; Hematology, Oncology and Palliative Medicine; Humans; Male; MicroRNAs - genetics; Middle Aged; MiR-15a; MiR-16-1; MiR-17-92 cluster; miRNA; Multigene Family; Multiple myeloma; Multiple Myeloma - drug therapy; Multiple Myeloma - genetics; Multiple Myeloma - mortality; Neoplasm Staging; Polymerase chain reaction; Prognosis; Real-Time Polymerase Chain Reaction; Survival; MiR-17-92 cluster; del; MiR-15a; MiR-16-1; Multiple myeloma
• ISSN: 0145-2126; 1873-5835
• DOI: 10.1016/j.leukres.2012.08.021

Abstract Multiple myeloma (MM) is characterized by a profound genomic instability of potential prognostic relevance. Loss of chromosome 13, observed in almost half of patients, negatively affects prognosis. MiR-15a, miR16-1 and miR-17-92 cluster, located on 13q, play important roles in the regulation of cell proliferation, differentiation and apoptosis. Therefore, we investigated a possible correlation of miRNA expression with chromosome 13 deletions (del(13)) and prognosis. We measured the expression of miR-15a, miR16-1 in 70 newly diagnosed MM patients and miR-17-92 cluster in 85 newly diagnosed MM patients by quantitative real-time PCR analyses. MiR-15a, miR-16-1 and miR-17-92 cluster expression levels are independent of the del(13). High levels of miR-15a, miR-16-1, miR-17, miR-20a and miR-92-1 are associated with shorter progression-free survival (PFS), suggesting poor prognosis. Our data suggest that the expression of specific miRNAs may be contributing to MM prognosis.